Home > Oncology > ASCO GU 2022 > Prostate Cancer > Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By
Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada
Conference
ASCO GU 2022
Trial
Phase 2, ACDC-RP
The first results of the phase 2 ACDC-RP trial show that 44% of patients with high-risk, clinically non-metastatic prostate cancer achieved either pathological complete response (pCR) or minimal residual disease (MRD) after neoadjuvant therapy with leuprolide plus abiraterone with or without cabazitaxel. High-risk, non-metastatic prostate cancer has a significant risk of recurrence when treated with unimodal therapy. The utility of neoadjuvant therapy prior to radical prostatectomy has yet to be defined. Therefore, the ACDC-RP trial (NCT02543255) investigated the use of abiraterone acetate/prednisone (AAP) and leuprolide with or without cabazitaxel prior to radical prostatectomy in patients with high-risk, clinically non-metastatic prostate cancer. Prof. Neil Fleshner (Princess Margaret Cancer Centre, Canada) presented the first results [1].


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on